CBD meets diabetes meds: could this combo tackle obesity and blood sugar?

NCT ID NCT06648031

First seen Jan 12, 2026 · Last updated Apr 29, 2026 · Updated 18 times

Summary

This early-phase study tested a special form of cannabidiol (CBD) called DehydraTECH, given alone or with popular GLP-1 drugs (like Ozempic), in 148 overweight or obese adults with prediabetes or type 2 diabetes. The goal was to see if the combination is safe and helps lower blood sugar and body weight more than either treatment alone. Participants took the medications for a set period, and researchers monitored side effects and changes in key health markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE2DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CMAX Clinical Research

    Adelaide, South Australia, 5000, Australia

  • Canopy Clinical Sutherland

    Miranda, New South Wales, 2228, Australia

  • Canopy Clinical Wollongong

    Wollongong, New South Wales, 2500, Australia

  • Emeritus - Melbourne

    Camberwell, Victoria, 3124, Australia

  • Emeritus - Sydney

    Botany, New South Wales, 2019, Australia

  • Paratus Clinical Brisbane Pty Ltd

    Herston, Queensland, 4006, Australia

  • Paratus Clinical Pty Ltd, Blacktown Trial Clinic

    Blacktown, New South Wales, 2148, Australia

Conditions

Explore the condition pages connected to this study.